New Zealand markets open in 4 hours 45 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7945-0.2021 (-20.28%)
At close: 04:00PM EST
0.7999 +0.01 (+0.68%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9966
Open0.9500
Bid0.7900 x 1000
Ask0.7907 x 900
Day's range0.7425 - 0.9601
52-week range0.3450 - 1.2800
Volume16,628,142
Avg. volume4,791,014
Market cap203.791M
Beta (5Y monthly)3.56
PE ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings date26 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.33
  • GlobeNewswire

    Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

    MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximat

  • GlobeNewswire

    Ocugen to Present at 2024 BIO CEO & Investor Conference

    MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 26-27, 2024, at the Marriott Marquis in New York City. Members of Ocugen’s leadership team will con

  • GlobeNewswire

    Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

    Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024. The event will ta